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Abstract
Health-Illness Transition Experiences Among Patients with Pancreatic Cancer
By
Jessica I. Goldberg
Advisor: Elizabeth Capezuti
Pancreatic cancer is one of the most commonly diagnosed cancers and is
associated with a poor prognosis measured in terms of months and with significant
palliative care needs, including psychological distress. Self-management describes a
patient’s ability to manage the sequelae of serious illness, which can have an impact on
quality of life and psychological health. One of the fundamental self-management skills
is the management of transitions. A transition is a change in life situation or status that
causes a shift in a patient’s identity, role, behavior, or interpersonal relationships.
Patients with cancer experience multiple, often overlapping transitions that can
influence their ability to self-manage.
The aim of this dissertation was to identify transitions experienced by patients
with pancreatic cancer and to measure their management of these transitions. This
study was guided by the Self- and Family Management Framework and Transitions
Theory. In this prospective longitudinal multi-method correlational study, a convenience
sample of 55 patients with pancreatic cancer from one medical oncology clinic at
Memorial Sloan Kettering Cancer Center were asked to report on their health-illness
transition experiences at two time-points with the Measurement of Transitions in Cancer
Scale (MOT-CA) and the Distress Thermometer (DT).
Patients reported experiencing multiple health-illness transitions and managed
these transitions moderately well. The patients experienced emotional distress, and
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there was a correlation between unmanaged transitions and distress at both time points.
Patients reported several new transition domains, including financial and caregiver
transitions, and described the impact of COVID-19 on their experience. Transitions were
found to influence the self-management practices of the patients. Barriers and
facilitators to active self-management were identified. Future research is needed to
better understand the transition experiences of patients with different tumor types and
disease course, and of family caregivers.

Keywords: transition, self-management, distress, pancreatic cancer
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Chapter 1: Background and Study Purpose
Background
Pancreatic cancer is one of the ten most commonly diagnosed cancers in both
men and women and is associated with a poor prognosis (Siegel, Miller, & Jemal,
2019). By 2030, pancreatic cancer will be the second most common cause of cancerrelated deaths (Rahib et al., 2014). The mortality rates for most cancer types have
declined during the past several decades due to improved screening, detection, and
treatment (Loud & Murphy, 2017); however, in pancreatic cancer, the death rate has
increased and the five-year survival is currently nine percent (J. Ma & Jemal, 2013;
Siegel et al., 2019). Patients with pancreatic cancer have significant palliative care
needs (Beesley et al., 2016), including high psychological distress (Carlson et al., 2018;
Clark, Loscalzo, Trask, Zabora, & Philip, 2010).
Psychological distress is a common experience for patients with cancer (Zabora,
BrintzenhofeSzoc, Curbow, Hooker, & Piantadosi, 2001). Twenty to 40% of all patients
with cancer, regardless of diagnosis with solid or hematologic malignancy, will
experience distress at some point during the disease trajectory (Mitchell et al., 2011).
Psychological distress, as described by the National Comprehensive Cancer Network,
is a multidimensional experience that can affect a patient’s ability to cope with a cancer
diagnosis and its consequences (2018). Several oncologic organizations have
published guidelines that highlight the importance of screening, diagnosis, and
management of distress in patients with cancer (Andersen et al., 2014; J. C. Holland et
al., 2013; Pirl et al., 2014). Despite the national spotlight on cancer-related distress,
many patients continue to experience unmet psychological needs, including untreated
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distress (J. C. Holland, 2013; Krebber, Jansen, Cuijpers, Leemans, & Verdonck-de
Leeuw, 2016; Zebrack et al., 2015).
Self-management is the process or series of tasks in which a patient participates
to manage the sequelae of serious illness (McCorkle et al., 2011). The degree to which
a patient engages in self-management may affect their quality of life and psychological
health, including the experience of cancer-related distress (Richard & Shea, 2011). A
key self-management skill is the management of transitions (McCorkle et al., 2011). A
transition is a shift that a patient experiences in life situation or status that brings about
a resultant change in their identity, role, behavior, or interpersonal relationships
(Schumacher & Meleis, 1994). Self-management can influence a patient’s ability to
respond to transitions in physical and emotional symptoms, spiritual well-being,
interpersonal relationships, functional ability and lifestyle (Richard & Shea, 2011).
Patients with cancer experience multiple, often simultaneous transitions, such as
physical, emotional, social, and spiritual changes (Geary & Schumacher, 2012).
Examples of transitions include changes in sleeping habits, anxiety, employment,
relationship with a higher power, and goal of treatment. These transitions can trigger
periods of increased distress (Schulman-Green, Bradley, et al., 2012) and can influence
a patient’s ability to self-manage (Schulman-Green et al., 2011). In patients with a poor
prognosis and limited life expectancy, such as those with a pancreatic cancer diagnosis,
the presence of multiple simultaneous transitions during a shortened period of time may
make self-management particularly difficult, leading to unmanaged transitions.
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Statement of the Problem
The aim of this dissertation was to identify transitions experienced by patients
receiving tumor-directed therapy for pancreatic cancer and to measure their
engagement with these transitions. This population, in whom survival is measured in
terms of months, is particularly at risk for poor health outcomes due to experiencing
multiple, simultaneous transitions that can cause distress over a brief period of time and
this distress can influence their self-management. We aimed to add to the nascent
health-illness transition literature and to describe the transition experiences of a
different population of patients with a unique disease trajectory.
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Significance of the Study
Patients with pancreatic cancer are at an especially high risk of developing
psychological distress (Carlson et al., 2018). There is evidence that cancer-related
distress has an adverse effect on quality of life (Zenger et al., 2010) and is associated
with increased overall mortality (Brown, Levy, Rosberger, & Edgar, 2003; Hamer,
Chida, & Molloy, 2009; Russ et al., 2012). Self-management can help to mitigate the
emotional experience of cancer, including the development of distress (Howell, Harth,
Brown, Bennett, & Boyko, 2017). Patients with a diagnosis of pancreatic cancer likely
have limited emotional capacity due to high levels of distress and a short amount of
time to learn and integrate self-management skills. Therefore, there is small window of
opportunity to reach these patients. In previous work, patients with ovarian and breast
cancer reported that simply acknowledging and discussing transitions was a validating
experience and played an important role in helping them to identify the source of their
distress (Goldberg, Hinchey, Feder, & Schulman-Green, 2016).
Management of transitions is an important self-management skill (SchulmanGreen, Jaser, et al., 2012), and previous research has demonstrated that patients with
breast (Schulman-Green et al., 2011) and ovarian cancer (Schulman-Green, Bradley, et
al., 2012) experience increased distress during times of transition. This relationship has
not yet been studied in other cancer populations; however, if it is shown to be more
widely applicable, this work may provide a foundation for an intervention to improve the
psychological health and quality of life for patients with cancer, including the particularly
vulnerable population of patients with pancreatic cancer.
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Purpose Statement and Research Questions
The specific aims of this study were:
Primary Aim 1: Identify the pattern(s) of transitions, the management of the transitions,
and the need for improvement in managing the transitions in patients with pancreatic
cancer who are receiving chemotherapy.
Hypothesis: Patients with pancreatic cancer will report multiple, overlapping healthillness transitions. They will report difficulty managing the personal and care transitions.
Exploratory Aim 1: Explore the relationship between demographic (gender, age, race)
and clinical (tumor type, time since diagnosis, stage) factors and the need for
improvement in managing transitions.
Hypothesis: In patients with pancreatic cancer, diagnosis with stage IV adenocarcinoma
and recent diagnosis will be associated with unmet transition needs.
Exploratory Aim 2: Explore the relationship between distress and the need for
improvement in managing transitions.
Hypothesis: Patients who report that they have unmanaged transitions will report
distress.
Qualitative Assessment: Conduct thematic analysis of the responses to the question (“Is
there anything else about your transition experience that you would like to add?”).

Conceptual Framework
The study of transitions is guided by the Self- and Family Management
Framework (Grey, Knafl, & McCorkle, 2006; Grey, Schulman-Green, Knafl, & Reynolds,
2015) and the Theory of Transitions (Schumacher & Meleis, 1994). The Self- and
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Family Management Framework describes how facilitators and barriers can influence
the process of self-management, which in turn affects individual and health outcomes in
patients with chronic illness (Grey et al., 2006; Grey et al., 2015) (Figure 1). Facilitators
and barriers that affect self-management include personal and lifestyle qualities, health
status, resources, environmental characteristics, and the health care system (Grey et
al., 2015). The framework describes three main self-management processes, focusing
on illness needs, activating resources, and living with the condition (Grey et al., 2015).
Although the framework does not use the language of “transitions”, it does highlight the
importance of acknowledging and managing change as a self-management task.
Specifically, the transition experience is reflected in the self-management process of
living with the condition, which in part describes a patient’s ability to adjust to and
integrate the chronic illness in their life.
Transition theory is a middle-range theory that provides a comprehensive view of
the transition experience and highlights the importance of the role of the nurse in this
process (A. I. Meleis, Sawyer, Im, Hilfinger Messias, & Schumacher, 2000; Schumacher
& Meleis, 1994). The theory describes four fundamental components: the nature of the
transition; facilitators and barriers to the transition; patterns of response; and nursing
therapeutics (A. I. Meleis et al., 2000) (Figure 2). Each of these components affects the
other bidirectionally. The nature of transitions encompasses the types, patterns, and
properties of the changes. The transition conditions, explained as the facilitators and
barriers, can be categorized as personal, community, and society. The patterns of
response include process indicators and outcome indicators.
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Transition theory demonstrates that transitions are complex experiences with
several fundamental properties, including awareness, engagement, change and
difference, time span, and critical points and events (A. I. Meleis et al., 2000).
Awareness refers to the knowledge and recognition that one is experiencing a
transition, which is one of the defining characteristic of a transition (Chick & Meleis,
1986). Engagement describes the degree of involvement in the processes of the
transition, such as seeking out help and information from medical providers and making
changes to one’s lifestyle (A. I. Meleis et al., 2000). Change and difference are essential
to the transition experience (A. I. Meleis & Trangenstein, 1994); all transitions are
triggered by a change, and all transitions result in a change. Critical points and events
are also important in the transition experience. Transitions are both triggered by a
critical point and cause a series of events to occur (A. I. Meleis et al., 2000).
The characteristics of the Self- and Family Management Framework and the
Theory of Transitions help to guide the aims of the study. Aim 1 tested fundamental
tenets of the transition experience, including the awareness and engagement with the
transition and the presence of changes and critical points. Additionally, Aim 1
acknowledged the importance of changes over time in the transition experience.
Therefore, in the study, patients were asked to identify the transitions they have
experienced and their engagement with the process at two different time points. The
experimental aims explored the patterns of response to transitions, and specifically
examined whether there is a relationship between the transition experience and the
presence of psychological distress.
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Chapter 2: Literature Review
In 2021, it is projected that almost two million new patients will be diagnosed with
cancer in the United States and more than six hundred thousand will die from cancer
(Siegel, Miller, Fuchs, & Jemal, 2021). Patients with cancer report a significant burden
which may be related to the cancer itself or to the treatment (Stark, Tofthagen,
Visovsky, & McMillan, 2012). The most commonly reported physical symptoms include
pain, fatigue, nausea/vomiting, and gastrointestinal issues (Deshields, Penalba, Liu, &
Avery, 2017; Wochna Loerzel, 2015). The most frequently reported psychological
symptoms include worry, anxiety, and depression (Deshields, Potter, Olsen, Liu, & Dye,
2011; Jimenez et al., 2011). The physical and psychological symptom burden
contributes to the prevalence of cancer-related distress in many patients (Mehnert et al.,
2018; Thiagarajan et al., 2016).

Pancreatic Cancer Treatment
Few patients diagnosed with pancreatic cancer have localized disease that will
allow for surgical resection (White & Lowy, 2017), and the majority will experience
recurrence of their disease (Sahin, Elias, Chou, Capanu, & O'Reilly, 2018). Therefore,
the NCCN guidelines recommend the use of adjuvant chemotherapy for all patients
diagnosed with pancreatic cancer (Tempero et al., 2019). The two most common
chemotherapy regimens for patients with pancreatic cancer are Gemcitabine/Abraxane
(Von Hoff et al., 2013) and FOLFIRINOX (Conroy et al., 2011). In the
Gemcitabine/Abraxane protocol, patients receive medication on days one, eight, and
fifteen, and the cycles of treatment repeat every 28 days. In the FOLFIRINOX protocol,
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patients receive Oxaliplatin, Irinotecan, and Leucovorin on day one, and Fluorouracil on
days one and two. The FOLFIRINOX cycle repeats every 14 days. Regardless of the
chemotherapy regimen, all patients undergo restaging scans every three months. These
treatments are associated with varied side effects, including fatigue, peripheral
neuropathy, neutropenia, thrombocytopenia, and anemia, which may be chronic and
have a significant impact on quality of life (Hronek & Reed, 2015).

Distress
The National Comprehensive Cancer Network (NCCN) defines distress as “a
multifactorial unpleasant experience… that may interfere with the ability to cope
effectively with cancer, its physical symptoms, and its treatment” (2018). Distress exists
along a continuum, and patients may develop feelings that range from sadness to
anxiety and depression, leading to a psychological crisis (National Comprehensive
Cancer Network, 2018). Over the past decade, there has been an increased focus on
the importance of distress to the cancer experience. In 2009, the International Psychooncology Society designated distress as the sixth vital sign (J. Holland, Watson, &
Dunn, 2011). In 2012, the American College of Surgeons Commission on Cancer
published guidelines which mandated routine distress screening as a requirement for
accreditation (Commission on Cancer, 2012).
Numerous systematic reviews and meta-analyses have addressed the potential
benefit of various interventions to decrease the distress burden of patients with cancer.
The results from many of these reviews are mixed (Chien, Liu, Chien, & Liu, 2014;
Faller et al., 2013; Graves, 2003; Hersch, Juraskova, Price, & Mullan, 2009), making it
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difficult to draw systematic conclusions. In addition, although the studies included
patients with various tumor types at different stages, the majority focused on women
with non-metastatic breast cancer (D'Egidio et al., 2017; Duijts, Faber, Oldenburg, van
Beurden, & Aaronson, 2011; Huang, He, Wang, & Zhou, 2016). There emerges a need
to better understand and to explore the distress experiences among a wider population
of patients.

Self-management
Self-management refers to the tasks that patients complete to manage a chronic
illness (Lorig & Holman, 2003) and improve overall quality of life (Schulman-Green,
Brody, Gilbertson-White, Whittemore, & McCorkle, 2018). The goal of self-management
is to maximize functioning and improve physical and psychological well-being (Barlow,
Wright, Sheasby, Turner, & Hainsworth, 2002). Integral self-management skills include
problem solving, goal setting, decision making, resource utilization, relationship-building
with health care providers, development of a plan for action, and self-tailoring (Lorig &
Holman, 2003). Self-management is a dynamic process that is relevant throughout the
cancer trajectory, from diagnosis to survivorship or end of life (McCorkle et al., 2011;
Schulman-Green et al., 2018). As the experience of living with cancer changes over
time, the self-management processes that are valuable to and helpful for a patient may
shift (Schulman-Green et al., 2018; Schulman-Green, Jaser, et al., 2012). There is a
strong bi-directional relationship between self-management and distress; selfmanagement skills can be used to decrease the experience of distress (Howell et al.,
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2017), but distress, in turn, can interfere with a patient’s ability to self-manage
(Schulman-Green, Jaser, Park, & Whittemore, 2016).

Transitions
A transition is a life change that influences a patient’s identity, relationships, and
behaviors (Schumacher & Meleis, 1994) and represents a central concept in nursing
practice (Im, 2011). The relationship between the nurse and the patient is often most
important during a time of transition (Harrison, 2004; A.I. Meleis, 2010). Nurses need to
be able to identify times of transition and to recognize how patients will react to
transition in order to be effective in their role and to ultimately affect the outcome of the
transition (Harrison, 2004; A.I. Meleis, 2010). The role of the nurse is to facilitate
transitions in their patients, namely to prevent risks from unmanaged transition and
changes due to the transitions, to promote good health, and to teach self-management
skills (A.I. Meleis, 2010; Schumacher & Meleis, 1994).
Transitions are complex but can be characterized by several key processes: an
inciting critical event such as a diagnosis of cancer and the subsequent awareness,
engagement, and adjustment by the patient over time (A.I. Meleis, 2010). The patient
engagement and adjustment over time are key steps in this process and are necessary
to ensure mastery or management of the transition experience. Unmanaged transitions
can result in worse health outcomes (A. I. Meleis et al., 2000). There are several
conditions that influence the experience of transitions. These include the meaning
individuals attach to a transition, their expectations for the transition, their level of
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knowledge or skill related to the transition, the surrounding environment, their level of
planning, and their emotional and physical well-being (Schumacher & Meleis, 1994).
Schumacher and Meleis described four distinct categories of transitions: developmental;
situational; organizational; and health-illness (1994). The experience of cancer patients
can best be explained as health-illness transitions, which are changes that occur with a
diagnosis of an illness (Schumacher & Meleis, 1994). The majority of the previous work
on health-illness transitions has focused narrowly on care transitions, which include
changes in cancer status, treatment type, or goals of care (Duggleby et al., 2010;
Kantsiper et al., 2009; Miller et al., 2015; Schulman-Green et al., 2011; Vaartio,
Kiviniemi, & Suominen, 2003); however, patients with cancer have reported that their
experience is not limited to care transitions and also endorse the importance of personal
health-illness transitions, which incorporate physical, emotional, social, and spiritual
changes (Schulman-Green, Jeon, McCorkle, & Dixon, 2017).
The health-illness transition experience of cancer patients is varied and complex.
While not a novel concept, cancer patients describe transitions as a new way of thinking
about times of change (Goldberg et al., 2016). Patients with breast cancer have
reported that transitions may be a positive, negative, or neutral experience (SchulmanGreen et al., 2011). They also describe that times of transitions are associated with
increased reliance on their support network (Schulman-Green et al., 2011).
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Chapter 3: Methods
Design
In this prospective longitudinal multi-method correlational study, a convenience
sample of patients with pancreatic cancer receiving tumor-directed therapy were asked
to report on their health-illness transition experiences.

Setting
Patients were approached for their voluntary participation in one medical
oncology clinic at Memorial Sloan Kettering Cancer Center (MSKCC). MSKCC is a
National Comprehensive Cancer Institute that serves an international population of
patients. The designated medical oncology clinic, led by a single attending oncologist,
cares primarily for patients with hepatobiliary malignancies, including pancreatic cancer.
This clinic was selected as it sees the highest volume of patients with pancreatic cancer
at MSKCC and would allow for standardization of the research practices. In 2017, over
750 new patients with a diagnosis of pancreatic cancer were seen at MSKCC.

Inclusion and Exclusion Criteria
The inclusion criteria for this study were: 1) adult patients 21 years of age and
older; 2) read and understand English; 3) biopsy-proven diagnosis of pancreatic cancer;
and 4) within the first three months after initiating chemotherapy at the Rockefeller
Outpatient Pavilion at MSKCC. The exclusion criterion was: 1) previous history of
cancer.
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Sample Size
For the study, we calculated sample size for our primary outcome, the
Measurement of Transitions in Cancer Scale (MOT-CA) (Schulman-Green et al., 2017),
using a two-tailed Wilcoxon signed-rank test and an alpha adjusted for multiple (7)
comparisons (alpha = 0.008) (Faul, Erdfelder, Lang, & Buchner, 2007). A sample size of
55 had 80% power to detect a change in MOT-CA between the two time points at a 5%
significance level.

Variables and Measures
Transitions.
Transitions were measured with The Measurement of Transitions in Cancer
Scale (MOT-CA) (Schulman-Green et al., 2017), a tool that was developed to identify
cancer-related transitions that patients experience and to measure how well they
believe they have managed each transition. There is a tool that measures exclusively
the site of care transitions (Coleman et al., 2002); the MOT-CA is the only scale that
exists to measure the complete health-illness transition experience. The MOT-CA
measures seven transition domains (physical, emotional, social, spiritual, cancer status,
treatment, approach to care) which correspond to seven health-illness transitions
reported by patients with breast and ovarian cancer (Schulman-Green et al., 2011;
Schulman-Green, Bradley, et al., 2012) and are guided by the Self- and Family
Management Framework (Grey et al., 2015). The seven transition domains of the MOTCA are categorized as either Personal (physical, emotional, social, spiritual) or Care
(cancer status, treatment, approach to care) Transitions. Factor analysis has
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demonstrated that Personal (α = 0.74) and Care (α = 0.79) are distinct and have an
inter-factor correlation of 0.323 (Jeon, Schulman-Green, McCorkle, & Dixon, 2019). The
only published use of this tool has been in population testing with breast cancer patients
(Goldberg et al., 2016).
The MOT-CA has seven items, and each item has two parts. The first part of
each item refers to the extent of the transition (part A) and the second part refers to the
management of the transition (part B). Thus, patients are first asked to rate the amount
of change they have experienced within the past month for each transition (from ‘0= no
change’ to ‘10= complete change’) and next how well they have dealt with the transition
(from ‘1= not well at all’ to ‘10= very well’). Patients can designate ‘no change’ and ‘N/A’
if they have not experienced a particular transition. The scores on part A can be
stratified; 1-3 means little transition, 4-6 means moderate transition, and 7-10 means
much transition (Schulman-Green et al., 2017). On part B, lower scores mean that the
transition was not managed well and higher scores mean that the transition was well
managed. The MOT-CA has not been used in the pancreatic cancer population. In an
effort to evaluate validity in this population, the author of the tool (DSG) agreed to allow
the researcher to add a question to the end of the assessment asking for additional
comments about the transition experience (‘Is there anything else about your transition
experience that you would like to add?’). After a review of the first several responses
and identification of several common themes, the researcher added several additional
questions including, “Did COVID affect your transition experience?”, Did you experience
any financial transitions?”, and Did you experience any caregiver transitions?”. The
responses to these questions were transcribed verbatim.
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Distress.
Distress was measured with the Distress Thermometer (DT), which was
developed by the NCCN Distress Management Panel ("NCCN practice guidelines for
the management of psychosocial distress. National Comprehensive Cancer Network,"
1999; Roth et al., 1998). The DT is one of the most commonly used tools to measure
distress in cancer patients (Donovan, Grassi, McGinty, & Jacobsen, 2014). The
reliability and validity of the DT has been described in multiple cancer populations
(Chambers, Zajdlewicz, Youlden, Holland, & Dunn, 2014; Gessler et al., 2008; X. Ma et
al., 2014; Wiener, Battles, Zadeh, Widemann, & Pao, 2017), although never specifically
in a pancreatic cancer population. All patients at Memorial Sloan Kettering receive the
DT as part of their new visit documentation.
The DT is a one item, 11-point visual analog scale superimposed on a graphic of
a thermometer. Patients are asked to rank how much distress they have experienced in
the past week on a scale that ranges from 0 (‘no distress’) to 10 (‘extreme distress’).
Scores less than four are reflective of mild distress, and any score of four or above
indicates clinically meaningful distress (J. C. Holland et al., 2013).

Demographic and Clinical Characteristics.
The following demographic and clinical data were collected from the electronic
medical record (EMR) to describe the sample: age; gender; race; date of diagnosis;
primary tumor histology; cancer stage; chemotherapy regimen; date of initiation of
chemotherapy; and date of death.
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Human Subject Considerations
Human subject approval was granted by the Institutional Review Board at
MSKCC (IRB #20-028) and the Human Research Protection Program (HRPP) at
CUNY/Hunter College (2020-0174).

Study Procedures
The researcher, as an employee of MSKCC and with the approval of the medical
clinical administrator and the MSKCC IRB, identified potentially eligible patients by
reviewing the medical oncology clinic list in the electronic medical record. A list of the
patients who met the study inclusion criteria was emailed to the medical team (medical
oncologist, nurse practitioner, and registered nurse) one business day before the clinic
was held. On the day of the clinic, the researcher (JG) approached the eligible patients
in the chemotherapy clinic suite for informed consent. Consented patients received a
number (assigned sequentially), which was used for identification on all study
documents, and they were asked to complete paper copies of the DT (Distress
Thermometer; ("NCCN practice guidelines for the management of psychosocial
distress. National Comprehensive Cancer Network," 1999; Roth et al., 1998) and the
and MOT-CA (Measurement of Transitions in Cancer Scale; (Schulman-Green et al.,
2017) (Time 1). The researcher also identified and documented demographic and
clinical variables from the EMR. The researcher tracked the patients’ subsequent
medical oncology visits using the EMR. Four to six weeks after the baseline visit, the
patients again completed the DT and MOT-CA at a chemotherapy treatment visit (Time
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2). This time point was chosen to follow patients long enough so that all had completed
at least one cycle of chemotherapy and had enough time to experience a transition,
although short enough that the majority of the patients had not become severely
debilitated. In the event that a patient did not complete assessments at both time points,
due to drop-out or death, they were not included the final analysis.

Data Management
The original paper copies of the study documents (consent form, DT, MOT-CA)
and the list linking the participants name to the participants study identification numbers
were housed in a locked file cabinet in a locked office which can only be accessed by
approved study personnel. Data collected for this study were entered by the researcher
without any personal identifiers into the Research Electronic Data Capture Database
(REDCap) (Harris et al., 2009). REDCap is an open-source platform that allows for the
secure collection of data using a web-based interface. Data was housed in the MSKCC
New Jersey data center. The MSKCC Information Systems group is responsible for
applying all operating system patches and security updates to the REDCap servers. All
connections to REDCap utilize encrypted (SSL-based) connections to ensure data is
protected and the server is backed up nightly. Only the MSKCC members of the
research personnel have access to this data.

Data Analysis
Quantitative Assessment.
The plan for data analysis was as follows:
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Frequencies and descriptive statistics were used to summarize the demographic
and clinical characteristics of the sample.
Primary Aim 1: Identify the pattern(s) of transitions, the management of transitions, and
the need for improvement in managing the transitions in patients with pancreatic cancer
who are receiving chemotherapy.
Frequencies and descriptive statistics were calculated for the transition variables
(presence of change, extent of the change, management of the change, and need for
improvement in management) at both time points. The proportional need for
improvement (NFI) in management score measures unmanaged transitions and is the
preferred method to analyze the correlation between extent of the transition and
management of the transition (Jeon et al., 2019). The NFI is calculated as [(10management of transition)/10] x extent of transition. A score of zero reflects either
successful management of the transition or a minor transition. The higher the NFI score,
the greater the need for improved management. Differences between the transition
variables at the two time points were calculated using a two-tailed Wilcoxon signed rank
test.
Hypothesis: Patients with pancreatic cancer will report multiple, overlapping healthillness transitions. They will report difficulty managing the personal transitions.

Exploratory Aim 1: Explore the relationship between demographic (gender, age, race)
and clinical (tumor type, time since diagnosis, stage) factors and the need for
improvement in managing transitions.
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The demographic and clinical factors were made into categorical (gender, race, tumor
type) and continuous (age, time since diagnosis) variables. The relationship between
the categorical factors (gender, race, tumor type) and the need for improvement in
managing transitions (NFI) for each of the seven transition domains was calculated
using a two-tailed Wilcoxon rank sum test. The relationship between the continuous
factors (age, time since diagnosis) and the need for improvement in managing
transitions (NFI) for each of the seven transition domains was calculated using
Spearman’s correlation.
Hypothesis: In patients with pancreatic cancer, diagnosis with stage IV adenocarcinoma
and recent diagnosis will be associated with unmanaged transitions.
Exploratory Aim 2: Explore the relationship between distress and the need for
improvement in managing transitions.
Frequencies and descriptive statistics were calculated for the distress score (on
the DT) at both time points. Correlation between the distress score and the need for
improvement in managing transitions were explored using Spearman’s correlation.
Hypothesis: Patients who report that they have unmanaged transitions will report
distress.

Qualitative Assessment.
The patient responses were synthesized using deductive thematic analysis;
familiarizing yourself with the data, generating initial codes, searching for themes, and
collapsing and redefining themes (Braun & Clarke, 2006). Two authors (EC and JG)
independently coded the patient responses using inductive analysis. They then
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compared and discussed their codes and resolved any discrepancies. Themes were
identified and the corresponding codes were grouped together. The final code key
consisted of five themes and nineteen codes and was applied to all of the patient
responses.
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Chapter 4: Results
Recruitment
154 patients were screened for eligibility, and 96 were deemed ineligible. Of the
58 eligible patients, 56 consented to participate in the study and completed the Time 1
data collection. One patient died before the Time 2 assessment and was not included in
the final analysis. In total, 55 patients completed the questionnaires at the two time
points (Figure 3).

Demographic and Clinical Characteristics
Approximately half of the sample was female (51%), and most were white (87%)
and older (Median age= 70 years, range 48-82). Median time from diagnosis to consent
was four months (range 0-50). Most of the participants had a diagnosis of stage IV
(75%) pancreatic adenocarcinoma (98%), and few (22%) had undergone a Whipple
procedure before study enrollment. The most common chemotherapy regimens were
FOLFIRINOX (45%) or Gemcitabine/Abraxane (31%) (Table 1).

Primary Aim 1
Frequency of Transitions.
The frequency of experiencing a transition ranged from 29 to 90% for all of the
transition domains at Time 1, with 50% or more patients describing at least some
physical, emotional, social, cancer status, and treatment transitions. At Time 2, the
frequency of transitions ranged from nine to 96% for the seven transition domains, with
proportions of 50% or more for physical, emotional, and social transitions only. The
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frequency of care transitions (cancer status, treatment, approach to care) significantly
decreased between Time 1 and Time 2 (p < 0.05) (Table 2).

Extent of Transitions.
Part A of the MOT-CA question asks about the extent of transition experienced.
Among those patients who reported experiencing a transition, the mean extent of
change ranged from 2.88 to 8.75 at Time 1 and from 2.42 to 8.38 at Time 2. At Time 1,
patients described much transition in cancer status and treatment. By Time 2, only
treatment transitions were frequently reported. Patients experienced moderate amounts
of physical and emotional transitions and little spiritual transitions at both time points.
Overall, the extent of each of the seven transition domains decreased between Time 1
and Time 2 (Table 3).

Management of Transitions.
Part B of the MOT-CA question asks about the management of the transition.
Among the patients who experienced a transition, the mean management ranged from
4.46 to 7.58 at Time 1 and from 4.62 to 7.68 at Time 2. Overall, the patients reported
that they managed all transitions at least moderately well. At both time points, patients
described better management of the personal transitions (physical, emotional, social), in
comparison to the care transitions (cancer status, treatment, approach to care) (Table
4).
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Need for Improvement in Managing Transitions.
The proportional need for improvement (NFI) is a composite score that combines
the extent and management of a transition (Jeon et al., 2019). The mean NFI score
ranged from 0.29 to 2.35 at Time 1 and from 0.17 to 2.12 at Time 2. Overall, the
patients reported successful management of the transitions at both time points. The
need for improvement in management significantly decreased for the care transitions
(cancer status, treatment, approach to care) between Time 1 and Time 2 (Table 5)

Exploratory Aim 1
At Time 1, women were more likely to have unmanaged emotional transitions
(2.50 vs 0.60, p = 0.002), and patients with locally advanced disease reported more
unmanaged social transitions (1.55 vs 0.40, p = 0.030). There were no statistically
significant relationships between the need for improvement in management composite
score and race, age, or time since diagnosis at either Time 1 or Time 2 (p > 0.05). Since
the majority of the sample (98%) had pancreatic adenocarcinoma (in comparison to
pancreatic neuroendocrine), tumor type was not included in the analysis.

Exploratory Aim 2
The level of distress reported by patients at all time points (first MSK visit, Time
1, Time 2) was unchanged (M = 3.87, 4.07, 4.02) (Table 6). At Time 1, patients with
greater levels of unmanaged physical, emotional, and cancer status transitions reported
more distress. At Time 2, patients with higher levels of unmanaged physical, emotional,
social, spiritual, cancer status, and treatment transitions experienced greater distress.
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The correlation between unmanaged emotional transitions and distress was moderate
(rs = 0.60) at Time 1 and high (rs = 0.82) at Time 2 (Hinkle, Wiersma, & Jurs, 2002)
(Table 7).

Qualitative Findings
Thirty-one of the patients provided 46 responses to the open-ended question
about their transition experience. The statements were organized into four themes:
alternate transition domains, characteristics of the transition, influence of the transition
on self-management, and facilitators and barriers to self-management (Table 8).

Alternate transition domains.
Patients identified several alternate transition domains that were not reflected on
the MOT; they included COVID transitions, financial transitions, and caregiver
transitions. Many of the patients described the influence of COVID-19 on their cancer
experience as a source of increased anxiety, social isolation, and in one patient who
had a concurrent diagnosis of COVID, increased vigilance and awareness of physical
symptoms. Several of the patients explained that the COVID-19 pandemic was the
source of a transition that was unique from any triggered by their cancer diagnosis.
COVID changed everything for us. My wife and I are both doctors and we
changed our practice to 100% telemedicine. I've totally isolated myself... we used
to be really social and would be out to dinner every night. Now I basically never
see friends in person. It's 100% from COVID, not the cancer.
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Patients frequently mentioned the financial changes that they experienced. For many of
these patients, the financial transitions included changes in job status or insurance
coverage. Several of the patients described these financial changes as a distinct
transition experience, which was associated with increased uncertainty and distress.
MSK doesn't take my insurance anymore so I'll be getting treatment at Yale.
Maybe this will be a good change… it's just been so expensive every time we
come into the city, it's been a constant problem. This is all a lot to take. I’m sure
it'll be fine in the end but it seems like a big deal now.
Many patients also reported their family caregivers experienced transitions as a result of
the patient’s cancer diagnosis.
My wife's life has changed a lot. She's definitely been praying more. She had to
go back to work. I don't know that she loves going back to work. I'm now Mr.
Mom around the house.

Characteristics of the transition.
Patient reported several characteristics of the transition, including that their
experience shifted throughout the disease course and that they frequently used
avoidance. Many patients described that the way that they engaged with and
experienced a transition changed over time. For many of these patients, the cancer
diagnosis acted as an inciting event which triggered multiple simultaneous changes or
transitions. Over time, patients became acclimated to the ways that these transitions
influenced their life.
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I think I'm pretty used to the ebb and flow by now. If you'd asked me in the
beginning it was a different story. My whole life had to change… cut back on
work hours, stopped going out, prayed much more. Now this seems like the new
normal.
Several patients described not wanting to acknowledge that they were experiencing a
transition.
There might be a difference between actual change and what someone might
acknowledge. I don't want to see changes in my body but if my wife was here she
might tell you something different.
These patients may have used avoidance as a protective measure against the
uncertainty and distress experienced during a transition.
I try not to think about all of it... I guess I'm the wrong person to ask. My wife
jokes that I could look past a burning house. It's always been easier to not think
too much about what's going on.

Influence of transition on self-management.
Patients described having difficulty engaging in self-management when they
were experiencing a transition. Physical transitions, most notably, changes in pain level,
affected patient’s ability to participate in self-management.
This month hasn't been great… it feels like it's catching up with me. The pain is
definitely worse now, that's really wearing me down. When I feel awful it's hard to
face anything else.
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The experience of emotional transitions, and the presence of uncertainty, also interfered
with self-management practices.
I feel suspended, like I'm attached to a wire. I can't go forward or backward.
There's so much uncertainty… that's been the biggest change. I can’t live my life.
I don't know what'll happen next. Makes it hard to know how to help myself.

Facilitators and barriers to self-management.
The patient reports several facilitators to participating in self-management,
including gaining knowledge and receiving support. Patients described the importance
of seeking out information about pancreatic cancer and its treatment and described
having a sense of control as a result of this knowledge.
Now I'm in a good place. I had to understand the data and pay attention to the
science to get past how scary the diagnosis is. Now I know the numbers and
that's been helpful.
Many of the patients identified the importance of social support in their coping,
particularly the support from their family caregivers.
My husband is my nurse. I used to do everything- cooking, cleaning. Now it’s all
him, he's a new man. I never asked him… expected him to do housework. Now
he spoils me. All this doesn't seem so bad because I have support.
Patients also described the importance of the support they received from their primary
oncology nurse. For many of these patients, the nursing support helped to alleviate
uncertainty and distress.
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I feel supported- that makes all the difference. The nurses here know what to
expect, they're always checking in and have something to recommend. I'm not
left to my own devices. I don't have to figure out how to cope when things
change.
One patient even explained that their family was having a more difficult time coping with
the changes because they did not have the same level of support from the nursing staff.
My kids have been having more difficulty with the day-to-day. Their lives have
changed more, I think more than me. I get to come here, I have the nurses for
support. My kids are more isolated- they're not the ones with cancer, they don't
have the same support.
Several patients described feeling supported by their religious beliefs and identified
prayer as an important self-management skill.
Prayer has been the most helpful. My faith gives me strength and when I'm
feeling challenged, stuck, I turn to prayer.

One of the most commonly cited barriers to participating in self-management was
financial difficulties. Many of the patients described feeling overwhelmed by the costs
associated with the cancer experience and the resulting financial strain.
There've been a lot of out-of-pocket costs I never expected. It's not even the big
things- the meds or treatment. It's been the small things that add up every month.
For treatment we take the train to the city, stay in a hotel, and then take cabs. It
really adds up. I think it's been the hardest part.
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Although caregiver support was frequently cited as a positive influence for patients,
many also described negative consequences as a result of their increased reliance on
the caregivers. Patients reported feeling dependency guilt and identified sources of
family stress.
My daughter's life absolutely changed in a heartbeat. I didn't expect her to
rearrange things so much in her life but it's been really helpful. Of course I feel
guilty, she should be living her own life, but instead she worries about me all the
time. I know it puts a lot of emotional strain on her.
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Chapter 5: Discussion
Summary
We found that patients with pancreatic cancer who were receiving chemotherapy
experienced multiple overlapping health-illness transitions; the most commonly reported
were physical, emotional, and social transitions. For most patients, the extent of the
transitions decreased by Time 2, four to six weeks after study enrollment. Overall,
patients reported that they managed these transitions moderately well, although the
personal transitions were managed better than the care transitions. The patients
experienced clinically significant levels of distress, which did not change over time.
There was a correlation between unmanaged transitions and distress at both time
points.
Patients’ descriptions of their overall transition experience confirmed much of the
previous understanding about health-illness transitions. The patients with pancreatic
cancer in this study described experiencing uncertainty during a transition and also
identified that their physical and emotional symptoms influenced the transition
experience (Schumacher & Meleis, 1994). Additionally, the patterns of transitions
reported by patients in this study were similar to those experienced by patients with
breast cancer (Goldberg et al., 2016). In both studies, the personal transitions (physical,
emotional, social, spiritual) were reported more frequently than the care transitions
(cancer status, treatment, approach to care). However, in the previous work with breast
cancer patients there was little difference in the management of the transitions; in the
current study, patients reported greater difficulty with management of the care
transitions. This finding may reflect the difference in prognosis between breast and
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pancreatic cancer; perhaps the patients with pancreatic cancer found managing their
transitions more difficult in the context of a poor prognosis.
The MOT-CA was designed to describe the broad categories of health-illness
transitions (Schulman-Green et al., 2017). This tool has not been extensively used in
previous research, though in this study, seemed to accurately reflect the overall
transition domains experienced by patients with pancreatic cancer. However, the
patients in this study did describe transitions that were not included in the MOT-CA.
Many patients reported experiencing significant financial stress and associated financial
transitions. This finding is consistent with a growing body of literature which highlights
that patients with advanced cancer may experience financial toxicity related to
transitions (Kayser, Smith, Washington, Harris, & Head, 2021) and often report that their
out-of-pocket costs were higher than they expected (Chino et al., 2017). There is
evidence that in patients with cancer, financial toxicity is associated with worse quality
of life outcomes (Arastu et al., 2020).
Additionally, many patients in this study described that their family caregivers
underwent their own transitions as a result of the cancer diagnosis. However, this is
from the patient’s perspective only; it is not yet clear whether the caregivers would
confirm this observation. The health-illness transition experience of family caregivers is
not well understood; much of the research focuses on the caregivers’ response when
their loved one undergoes a transition (Petrin, Bowen, Alfano, & Bennett, 2009; Wong,
George, Godfrey, Le, & Pereira, 2019). Future iterations of the MOT-CA should
incorporate these findings and evaluate for the presence of financial and caregiver
transitions.
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One unexpected finding from this study was that overall, the patients reported
only moderate levels of transitions. The frequency of transitions was similar between the
sample of patients with non-metastatic breast cancer in previous work (Goldberg et al.,
2016) and in this sample of patients with advanced and metastatic pancreatic cancer.
One possible explanation for this finding may be that patients are unaware or unwilling
to acknowledge the presence of a transition. It is possible that there is a difference
between unconscious and conscious transitions (Fringer, Hechinger, & Schnepp, 2018).
For example, a patient in the early stages of a social transition may start to
unconsciously demonstrate increased reliance on their family caregiver. This change
could continue unconsciously until the patient and their caregiver are forced to be active
in the process and make adjustments to their behavior and decisions. In the seminal
work on transition theory, awareness of the transition was identified as a key property of
the transition experience (Chick & Meleis, 1986). However, more recent scholarship has
challenged this and suggested that a transition may exist regardless of the
acknowledgement by the patient; these authors describe that the nurse’s knowledge of
the transition may be sufficient (A. I. Meleis et al., 2000). Perhaps the use of only patient
self-report for the identification of transitions is not sufficient to accurately describe the
transition experience.

Implications for Nursing
Nurses have an opportunity and a responsibility in shaping the health-illness
transition experience of patients with cancer. The role of the nurse has always been an
important component of the transition theory (Chick & Meleis, 1986) and nurses can
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influence the preparation for and education and management of health-illness
transitions (Schumacher & Meleis, 1994). Palliative care and hospice nurses in
particular, are “transition specialists” (Ferrell, 2021) and are uniquely suited to guide
patients through the transition experience.

Limitations
Our study has a few limitations, including that the sample of patients was largely
homogenous in its racial background. In the United States, Black individuals are more
likely to be diagnosed with and die from pancreatic cancer as compared to whites
regardless of age (Zavala et al., 2021). As a result, it is unclear if the findings from this
study would be generalizable to a larger, more diverse population. Additionally, the
patients were eligible for enrollment if they were receiving chemotherapy, and therefore
patients who were being treated with immunotherapy and other targeted treatments
were excluded. As the second- and third-line treatment options for pancreatic cancer
continue to evolve beyond the traditional chemotherapy regimens (Sohal et al., 2020),
patients may have different transition experiences. The patient sample was also
consented from a single oncology clinic in a dedicated cancer center, and therefore may
not be generalizable to a different care setting. In addition, the results may have been
influenced by the study time period. The timeframe may have been too short for some
of the patients to experience a transition, or to acknowledge the presence of a
transition.
The most significant limitation that may have influenced the data of this study
was the presence of the COVID-19 pandemic. The patients in this study were all
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enrolled several months after the appearance of COVID in the United States. Cancer
care was influenced by COVID; many visits with the oncologist were switched from inperson to telemedicine, and patients were no longer allowed to have companions during
office visits or while receiving treatment (Al-Shamsi et al., 2020). These changes may
have influenced the transition experience by changing the relationship between the
patient and the health-care providers or by impacting the involvement of the family
caregivers. Several of the patients enrolled in this study had a previous or concurrent
diagnosis of COVID and many described the COVID pandemic as a source of increased
distress and uncertainty.

Conclusion
This study describes health-illness transition experiences of patients with
pancreatic cancer and adds to the nascent literature about how the extent and
management of transitions varies by tumor type. Future research should focus on the
experience of patients with cancers that follow a different disease course, such as
patients with hematologic malignancies who are treated with the expectation for cure,
minority patients, and those who are uninsured. In addition, more research is needed to
identify and describe transition domains particular to family caregivers.
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Appendix
Appendix Figures

Figure 1. Revised Self- and Family Management Framework
Grey, M., Schulman-Green, D., Knafl, K., & Reynolds, N. R. (2015). A revised Self- and
Family Management Framework. Nurs Outlook, 63(2), 162-170.
doi:10.1016/j.outlook.2014.10.003
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Figure 2. Transition Theory
Meleis, A. I., Sawyer, L. M., Im, E. O., Hilfinger Messias, D. K., & Schumacher, K.
(2000). Experiencing transitions: an emerging middle-range theory. ANS Adv Nurs Sci,
23(1), 12-28.
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Figure 3. Cohort Diagram
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Appendix Tables
Table 1. Demographic and Clinical Characteristics
Characteristic
n (%)
Median (Range)
Age
At diagnosis
70 (46-82)
At consent
70 (48-82)
Sex
Female
28 (50.9)
Male
27 (49.1)
Race
Asian
6 (10.9)
Black
1 (1.8)
White
48 (87.3)
Time from diagnosis to consent
4 (0-50)
(month)
Tumor type
Adenocarcinoma
54 (98.2)
Neuroendocrine
1 (1.8)
Stage
II
10 (18.2)
III
4 (7.3)
IV
41 (74.5)
Surgery
No
43 (78.2)
Yes
12 (21.8)
Chemotherapy
FOLFIRINOX
25 (45.5)
Gemcitabine/Abraxane
17 (30.9)
FOLFIRI
7 (12.7)
FOLFOX
4 (7.3)
Gemcitabine/Capecitabine
1 (1.8)
Gemcitabine/Cisplatin/Abraxane
1 (1.8)
Note. FOLFIRINOX = folinic acid, fluorouracil, irinotecan, and oxaliplatin; FOLFIRI =
folinic acid, fluorouracil, irinotecan; FOLFOX = folinic acid, fluorouracil, oxaliplatin
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Table 2. Frequency of Transitions (N = 55)
Transition Item
Time 1
Time 2
n (%)
n (%)
Physical
52 (95)
53 (96)
Emotional
Social
Spiritual
Cancer status
Treatment
Approach to
care
* McNemar’s Test

51 (93)
44 (80)
24 (44)
28 (51)
32 (58)
16 (29)

53 (96)
39 (71)
19 (35)
16 (29)
8 (15)
5 (9)

p value*
>0.9
0.7
0.3
0.4
0.025
<0.001
0.010
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Table 3. Descriptive Statistics for Extent of Transitions
Transition Item
Time 1
Time 2
n
M
SD
Mdn
n
M
SD
Mdn
Physical
52 5.00 2.14 5.00
53 4.70 1.85 5.00
Emotional
51 4.73 2.50 5.00
53 4.43 2.37 4.00
Social
44 4.14 3.15 3.00
39 2.72 2.05 2.00
Spiritual
24 2.88 2.05 2.00
19 2.42 1.64 2.00
Cancer status
28 7.00 3.20 8.00
16 4.44 2.53 3.50
Treatment
32 8.75 2.14 10.00
8 8.38 2.83 10.00
Approach to
16 5.25 3.36 5.00
5 3.20 2.17 2.00
care
Note. Data are based on the number of participants who reported experiencing a
transition for each transition domain. Higher scores indicate more change. M = mean;
SD = standard deviation, Mdn = median
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Table 4. Descriptive Statistics for Management of Transitions
Transition Item Time 1
Time 2
n
M
SD
Mdn
n
M
SD
Mdn
Physical
52 6.04 1.98
6.00
53 6.02 1.90 6.00
Emotional
51 5.94 2.10
6.00
53 5.98 2.15 6.00
Social
44 6.91 1.91
7.00
39 6.77 1.95 7.00
Spiritual
24 7.58 1.35
8.00
19 7.68 1.25 8.00
Cancer status
28 4.46 1.93
4.50
16 6.19 2.23 6.00
Treatment
32 5.59 1.98
5.00
8 4.62 2.00 4.50
Approach to
16 5.94 1.69
5.00
5 4.80 1.79 6.00
care
Note. Data are based on the number of participants who reported experiencing a
transition for each transition domain. Higher scores indicate better management. M =
mean; SD = standard deviation, Mdn = median
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Table 5. Descriptive Statistics for Proportional Need for Improvement (NFI) Composite
Score (N= 55)
Transition
Time 1
Time 2
p value*
Item
M
SD
Mdn
M
SD
Mdn
Physical
2.15 1.77
1.60
2.07 1.67
1.60
0.6
Emotional
2.08 2.01
1.60
2.12 2.03
1.40
0.8
Social
1.18 1.70
0.50
0.83 1.34
0.30
0.10
Spiritual
0.29 0.56
0.00
0.21 0.50
0.00
0.4
Cancer
2.12 2.68
0.00
0.56 1.37
0.00
<0.001
status
Treatment
2.35 2.52
1.50
0.67 1.88
0.00
0.002
Approach to
0.66 1.39
0.00
0.17 0.73
0.00
0.028
care
Note. The Proportional Need For Improvement (NFI) is a measure of unmanaged
burden of transition. Proportional NFI scores of zero could represent either fully
successful management or absence of the transition. Higher scores indicate a greater
extent of unmanaged transition. M = mean; SD = standard deviation, Mdn = median
* Wilcoxon signed rank test
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Table 6. Distress Score by Time
Time Point
n
First MSK visit
51
Time 1
55
Time 2
55
Note. SD = standard deviation

Mean
3.87
4.07
4.02

SD
2.92
2.15
2.04

44

Median
4.00
4.00
3.00
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Table 7. Correlation Between Proportional Need for Improvement (NFI) Composite
Score and Distress (N = 55)
Transition Item Time 1
Time 2
rs
rs
Physical
0.40**
0.59**
Emotional
0.60**
0.82**
Social
0.19
0.71**
Spiritual
0.09
0.49**
Cancer status
0.28*
Treatment
0.06
Approach to
0.21
care
Note. rs = Spearman’s rank correlation coefficient
* p < .05. ** p < .01.

0.48**
0.33*
0.21
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Table 8. Transition Themes
Themes
Alternate transition domains

Characteristics of the transition
Influence of transition on selfmanagement
Facilitators and barriers to selfmanagement

46

Codes
Financial transition
Caregiver transition
COVID transition
Change over time
Avoidance
Overwhelmed by physical symptoms
Overwhelmed by emotional symptoms
Overwhelmed by prognosis
In control with knowledge
Feels supported by family caregiver
Feels supported by nurse
Feels supported by religion/prayer
Self-support
Financial difficulties
Lack of support
Conflicting demands
Dependency guilt
Role change
Family stress
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